October 22, 2018
It’s plagued by incomplete analysis and missing data, yet the Institute for Clinical and Economic Review’s draft evidence report on severe asthma medicine still manages to deliver a familiar refrain. All five of the drugs reviewed, ICER reports, are not cost-effective.
October 17, 2018
The Institute for Clinical and Economic Review says new medicine for uncontrolled asthma isn’t worth its cost. But its analysis…
October 2, 2018
Oklahoma is leading the nation when it comes to innovative drug pricing approaches.
September 20, 2018
For inmates in Colorado who have hepatitis C, the wait for treatment is almost over.
August 30, 2018
Patient access developments didn’t stop for summer. As we head into fall, here are 10 quotes from the news items – and new materials – that kept the health policy conversation lively during summer 2018.
August 28, 2018
CVS Health recently announced that employers who use its pharmacy benefit management services can cut certain medications from their plan’s formulary of approved drugs. Which drugs? Those that exceed a cost-effectiveness threshold established by ICER, the Institute for Clinical and Economic Review.
August 9, 2018
An influential calculation of how new drugs impact annual spending is flawed – and patients may be paying the price in reduced access to innovative medicine.
July 24, 2018
To import, or not to import? The question of whether to bring foreign, lower-priced versions of prescription drugs to the United States is back.
June 29, 2018
Massachusetts Medicaid patients are breathing a collective sigh of relief.
June 8, 2018
Economists at the Institute for Clinical and Economic Review advise a whopping 77 percent price discount on new CFTR modulators for cystic fibrosis, according to a final evidence report. The drugs can “substantially improve patient health outcomes,” the group concedes, but their prices exceed ICER’s cost-effectiveness threshold. One manufacturer has called ICER’s analysis “a sham.”
